IMBRUVICA (ibrutinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·CHRONIC LYMPHOCYTIC LEUKEMIA·+5
PHARMACYCLICS,
Indication
Waldenstrom's macroglobulinemia
Waldenstrom's macroglobulinemia is an indolent, rare B-cell lymphoproliferative disorder classified as a distinct subtype of non-Hodgkin lymphoma. Read more about Waldenstrom's macroglobulinemia
3 drugs 2 manufacturers
Drugs that treat it
Common Waldenstrom's macroglobulinemia therapies.
IMBRUVICA (ibrutinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·CHRONIC LYMPHOCYTIC LEUKEMIA·+5
PHARMACYCLICS,
BRUKINSA (zanubrutinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·CHRONIC LYMPHOCYTIC LEUKEMIA·+5
BEONE MEDICINES
Filter & compare in the drug finder →Opens the drug finder with Waldenstrom's macroglobulinemia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonWaldenstrom's macroglobulinemia is an indolent, rare B-cell lymphoproliferative disorder classified as a distinct subtype of non-Hodgkin lymphoma.
Primarily affecting the bone marrow, lymphatic system, and peripheral circulation of older adults, the condition is pathophysiologically defined by clonal lymphoplasmacytic cell infiltration accompanied by excessive monoclonal immunoglobulin M (IgM) production.
Progressive clonal expansion and circulating pentameric IgM frequently cause cytopenias—predominantly normocytic anemia—along with hepatosplenomegaly, lymphadenopathy, peripheral neuropathy, and serum hyperviscosity syndrome.
Highly recurring somatic mutations, most notably in the *MYD88* gene, are characteristic molecular hallmarks of the disease.
- cancer.gov
Waldenstrom's macroglobulinemia is an indolent, rare B-cell lymphoproliferative disorder classified as a distinct subtype of non-Hodgkin lymphoma
- nih.gov
Waldenstrom's macroglobulinemia is an indolent, rare B-cell lymphoproliferative disorder classified as a distinct subtype of non-Hodgkin lymphoma Primarily affecting the bone marrow, lymphatic system, and peripheral circulation of older adults, the condition is pathophysiologically defined by clonal lymphoplasmacytic cell infiltration accompanied by excessive monoclonal immunoglobulin M (IgM) production
- nih.gov
Waldenstrom's macroglobulinemia is an indolent, rare B-cell lymphoproliferative disorder classified as a distinct subtype of non-Hodgkin lymphoma Primarily affecting the bone marrow, lymphatic system, and peripheral circulation of older adults, the condition is pathophysiologically defined by clonal lymphoplasmacytic cell infiltration accompanied by excessive monoclonal immunoglobulin M (IgM) production Progressive clonal expansion and circulating pentameric IgM frequently cause cytopenias—predo...
- iwmf.com
Primarily affecting the bone marrow, lymphatic system, and peripheral circulation of older adults, the condition is pathophysiologically defined by clonal lymphoplasmacytic cell infiltration accompanied by excessive monoclonal immunoglobulin M (IgM) production
- nih.gov
Progressive clonal expansion and circulating pentameric IgM frequently cause cytopenias—predominantly normocytic anemia—along with hepatosplenomegaly, lymphadenopathy, peripheral neuropathy, and serum hyperviscosity syndrome
- nih.gov
Progressive clonal expansion and circulating pentameric IgM frequently cause cytopenias—predominantly normocytic anemia—along with hepatosplenomegaly, lymphadenopathy, peripheral neuropathy, and serum hyperviscosity syndrome
- nih.gov
Highly recurring somatic mutations, most notably in the *MYD88* gene, are characteristic molecular hallmarks of the disease
- medlineplus.gov
Highly recurring somatic mutations, most notably in the *MYD88* gene, are characteristic molecular hallmarks of the disease
Personalize your experience
Follow Waldenstrom's macroglobulinemia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.